Why Clinical Research Matters: A 14-year-old’s Perspective on Her Experience in the GenARA Trial
Patients and their families play one of the most important roles in clinical research.
STAT News First Opinion: DCRI’s Perakslis Pens Op-ed on Proposed Health Data Rulemaking
Duke Clinical Research Institute Chief Digital and Science Officer Eric Perakslis, PhD, co-authored an opinion piece with Katie D.
Three DCRI Faculty Receive Distinguished Professorships
The Duke Clinical Research Institute celebrates three of its faculty members who were recently awarded distinguished professorships.
Research Study on Comfort of the New FLUME Catheter to Begin Recruitment
Duke Clinical Research Institute and Penn State College of Medicine Partner to Collect Patient Insight on Innovative FLUME Catheter
Duke-led consortium envisions new plan for organ transplant management
Organ transplant patients in the U.S. deserve better.
Sixth Pharmaceutical Company Joins the CardioHealth Alliance, Further Expanding Reach and Impact of Evidence-Based Prevention and Care
CardioHealth Alliance welcomed Novo Nordisk Inc.
DCRI HEAL Connections Team Assembles Naloxone Kits at Team Building Event
At least 100 of the 500 naloxone kits assembled by the DCRI’s HEAL Connections team members in March will likely be used to help reverse opioid overdoses and possibly save lives.
DCRI Releases 2022 Impact Report
At the DCRI, we’re bringing creative solutions to the world’s most vexing health problems.
Boehringer Ingelheim and Eli Lilly and Company Join CardioHealth Alliance
A consortium called the CardioHealth Alliance brings together a multi-disciplinary group of experts to improve the care and health of patients across cardiovascular, renal and metabolic diseases.
Laos, Malawi, Rwanda and Zambia Receive Oral Antiviral Treatments for High-Risk Patients Through COVID Treatment Quick Start Consortium
The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer’s COVID-19 o